NASDAQ · Software - Application
WALD (WALD) Stock
$1.67
-2.91%
NASDAQ: WALD
Technology
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Waldencast Says US FDA Approves Obagi Saypha ChIQ Injectable Hyaluronic Acid Gel
MT Newswires · Jun 15, 2026
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
GlobeNewswire · Jun 15, 2026
June 2026's Promising Penny Stocks To Watch
Simply Wall St. · Jun 11, 2026
Waldencast Announces Sale of Obagi Medical to Bridgepoint
GlobeNewswire · Jun 1, 2026
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
GlobeNewswire · May 15, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held50.95%
Institutions Held25.68%
Institutions Float Held52.36%
Peer Comparison
About WALD
WALD is led by CEO Michel Brousset, employs 335 people, headquartered in US, publicly traded since 2021.
WALD stock trades at $1.67 with a market capitalization of $197.46M. The stock is valued at a price-to-earnings (P/E) ratio of -0.83, price-to-book of 0.43, price-to-sales of 0.64. Over the past 52 weeks the stock has ranged between $0.72 and $3.22, and currently trades 48.1% below its 52-week high.
On profitability, WALD generates a return on equity (ROE) of -49.78%, return on capital employed of -12.40%, an operating margin of -22.79%, a net profit margin of -84.44%.